Nexium and Foscavir drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Nexium (esomeprazole magnesium) and Foscavir (foscarnet sodium). Common drug interactions include septic shock among females and alanine aminotransferase increased among males.

The phase IV clinical study analyzes what interactions people have when they take Nexium and Foscavir. It is created by eHealthMe based on reports of 33 people who take the same drugs from the FDA, and is updated regularly.

What is Nexium?

Nexium has active ingredients of esomeprazole magnesium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 245,678 Nexium users. Check the latest studies of Nexium.

What is Foscavir?

Foscavir has active ingredients of foscarnet sodium. eHealthMe is studying from 1,631 Foscavir users. Check the latest studies of Foscavir.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 17, 2026

33 people who take Nexium and Foscavir together, and have interactions are studied.

Nexium and Foscavir drug interactions.

What are the common drug interactions of Nexium and Foscavir, by gender? *:

female:

  1. Septic shock (shock due to blood infection)
  2. Angioimmunoblastic t-cell lymphoma (mature t-cell cancer of the blood or lymph vessel)
  3. Bronchopulmonary aspergillosis (lung disorder caused by aspergillus fungi)
  4. Enterococcal bacteraemia (presence of bacteria lactic acid in the blood)
  5. Liver disorder (liver diseases)
  6. Pancreatitis acute (sudden inflammation of pancreas)
  7. Posterior reversible encephalopathy syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss)
  8. Systemic candida (whole body fungal infection)
  9. Renal failure acute (rapid kidney dysfunction)
  10. Antithrombin iii deficiency (rare hereditary disorder that generally comes to light when a patient suffers recurrent venous thrombosis and pulmonary embolism, and repetitive intrauterine fetal death (iufd))

male:

  1. Alanine aminotransferase increased
  2. Aspartate aminotransferase increased
  3. Cardiac failure
  4. Colitis ischaemic (due to infection of intestine impaired blood supply to colon)
  5. Cytomegalovirus viraemia (cytomegalo virus in blood stream)
  6. Diffuse large b-cell lymphoma (cancer of b cells, a type of white blood cell)
  7. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  8. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  9. Ventricular tachycardia (rapid heartbeat that originates in one of the lower chambers (the ventricles) of the heart)
  10. Anaemia (lack of blood)

What are the common drug interactions of Nexium and Foscavir, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Bone marrow failure
  2. Asthma
  3. Bacterial infection
  4. Chest pain
  5. Cough
  6. Cystitis haemorrhagic (blood in the urine and painful voiding)
  7. Cytomegalovirus viraemia (cytomegalo virus in blood stream)
  8. Delirium (wild excitement)
  9. Diarrhoea
  10. Disseminated intravascular coagulation (systemic activation of blood coagulation)

40-49:

  1. Renal tubular disorder (disease of kidney tubules)
  2. Blood creatinine increased
  3. Cytolytic hepatitis (dissolution or destruction of a liver cell)
  4. Drug rash with eosinophilia and systemic symptoms (adverse drug reactions with rash)
  5. Haematuria (presence of blood in urine)
  6. Hypoalbuminaemia (levels of albumin in blood serum are abnormally low)
  7. Nephrotic syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema)
  8. Proteinuria (presence of protein in the urine)
  9. Renal failure acute (rapid kidney dysfunction)
  10. Sepsis (a severe blood infection that can lead to organ failure and death)

50-59:

  1. Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)
  2. Renal failure acute (rapid kidney dysfunction)
  3. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  4. Anaemia (lack of blood)
  5. Cardiac arrest
  6. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  7. Confusional state
  8. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  9. Escherichia sepsis (bacterial infection by escherichia coli)
  10. Fall

60+:

  1. Septic shock (shock due to blood infection)
  2. White blood cell count decreased
  3. Cardiac failure
  4. Colitis ischaemic (due to infection of intestine impaired blood supply to colon)
  5. Cytomegalovirus enterocolitis (virus infection of intestine and colon)
  6. Diarrhoea
  7. Diffuse large b-cell lymphoma (cancer of b cells, a type of white blood cell)
  8. Febrile neutropenia (fever with reduced white blood cells)
  9. Pneumonia
  10. Pulmonary oedema (fluid accumulation in the lungs)

What are the existing conditions these people have? *

  1. Cytomegalovirus Infection: 11 people, 33.33%
  2. Angioimmunoblastic T-Cell Lymphoma (mature t-cell cancer of the blood or lymph vessel): 5 people, 15.15%
  3. Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 4 people, 12.12%
  4. Adverse Event: 4 people, 12.12%
  5. Septic Shock (shock due to blood infection): 4 people, 12.12%
  6. Cystitis Haemorrhagic (blood in the urine and painful voiding): 4 people, 12.12%
  7. Haemolytic Uraemic Syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more): 3 people, 9.09%
  8. Fever: 3 people, 9.09%
  9. Hiv Infection: 3 people, 9.09%
  10. Cytomegalovirus Enterocolitis (virus infection of intestine and colon): 3 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Nexium and Foscavir?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Nexium and Foscavir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Nexium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Foscavir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Nexium and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Foscavir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on esomeprazole magnesium and foscarnet sodium (the active ingredients of Nexium and Foscavir, respectively), and Nexium and Foscavir (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: